Although rare, invasive meningococcal disease remains an important cause of 
mortality and morbidity in children and young adults. Vaccines have been 
successfully introduced to help protect against meningococcal disease caused by 
serogroups A, C, W and Y, but until recently, a vaccine for serogroup B (MenB) 
was not available. In many industrialised countries, MenB causes the majority of 
meningococcal disease. Moreover, MenB outbreaks occur unpredictably, 
particularly in high-risk populations, such as university students. In 2013, 
Bexsero(®) became the first broad-coverage vaccine to be licensed for active 
immunisation against MenB disease. Bexsero is now licensed in more than 35 
countries worldwide for varying age groups, including the EU, Australia, Brazil, 
Canada, Chile, Uruguay and the USA. Clinical recommendations for the use of 
Bexsero have been published in several countries. Recommendations include use in 
high-risk groups, outbreak control and routine infant immunisation. Since 
initial licensure, considerable clinical experience has been gained. In Canada, 
43,740 individuals received Bexsero during a vaccination programme in the 
Saguenay-Lac-Saint-Jean region of Quebec, where local disease incidence was 
high. In the USA, Bexsero was administered to >15,000 individuals during two 
college outbreaks prior to licensure, under an Investigational New Drug 
protocol. In the UK, the Joint Committee on Vaccination and Immunisation has 
recommended the inclusion of Bexsero in the routine immunisation schedule for 
infants. Publically funded vaccination programmes have been initiated in Italy, 
and there has been widespread use of the vaccine outside of publically 
reimbursed programmes. Overall, >1,000,000 doses of Bexsero have been 
distributed in 19 countries worldwide since 2013. The emerging clinical 
experience with Bexsero is consistent with findings from pre-licensure clinical 
studies, and no new safety concerns have been identified. Additional data on 
length of protection, potential impact on meningococcal carriage and 
transmission and strain coverage have also been published and will be reviewed.